Impact of adjuvant imatinib on bone and muscle density in patients with resected gastrointestinal stromal tumors
-
Published:2022-06
Issue:
Volume:34
Page:100422
-
ISSN:2212-1374
-
Container-title:Journal of Bone Oncology
-
language:en
-
Short-container-title:Journal of Bone Oncology
Author:
Fulgenzi Claudia Angela Maria,
Napolitano AndreaORCID,
Faiella Eliodoro,
Messina Laura,
Castiello Gennaro,
Paternostro Flavia,
Silletta Marianna,
Pantano Francesco,
Tonini Giuseppe,
Santini Daniele,
Vincenzi Bruno
Reference30 articles.
1. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era–a population-based study in western Sweden;Nilsson;Cancer.,2005
2. Mazzocca A, Napolitano A, Silletta M, Spalato Ceruso M, Santini D, Tonini G, et al. New frontiers in the medical management of gastrointestinal stromal tumours. Ther Adv Med Oncol. 2019;11:1758835919841946.
3. FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance;Taylor;Oncogene.,2006
4. Imatinib Mesylate;Waller;Recent Results Cancer Res.,2018
5. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms;O'Sullivan;J Bone Miner Res.,2007
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献